PMID: 9222866Jan 1, 1994Paper

A new approach for the detection of type III hyperlipoproteinemia by RLP-cholesterol assay

Journal of Atherosclerosis and Thrombosis
Katsuyuki NakajimaT Murase

Abstract

Type III is a remnant hyperlipoproteinemia identified by the presence of beta-VLDL (remnant lipoprotein) as well as a genetic variant of apo E (apo E2/2). The RLP isolated from the serum of Type III patients by a new method we have developed, the RLPcholesterol assay, was identified as chylomicron and VLDL remnant. In addition, the RLP-C levels of the Type III patients were significantly higher than other hyperlipidemic patients with similar serum TG levels, while the ratio of TC/TG in RLP-C of both groups was not significantly different. The RLP-cholesterol assay appears to be useful for the screening and monitoring of Type III hyperlipoproteinemia when used in conjunction with the assays of serum TG level and genetic apo E isoform analysis.

References

Jan 1, 1986·Methods in Enzymology·I Hara, M Okazaki
Jul 1, 1973·Proceedings of the National Academy of Sciences of the United States of America·R J Havel, J P Kane
Jan 1, 1983·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·J P KaneR J Havel
Jul 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·R J HavelL S Guo
Sep 1, 1955·The Journal of Clinical Investigation·R J HAVELJ H BRAGDON

❮ Previous
Next ❯

Citations

Apr 15, 1995·Thrombosis Research·R KnöflerA Takada
Aug 14, 1995·Clinica Chimica Acta; International Journal of Clinical Chemistry·R KnöflerA Takada
Nov 6, 2007·Clinica Chimica Acta; International Journal of Clinical Chemistry·Tetsuo YamadaAkira Tanaka
Jul 24, 2007·Clinica Chimica Acta; International Journal of Clinical Chemistry·Hiroe SatoFumitake Gejyo
Sep 18, 2012·Clinica Chimica Acta; International Journal of Clinical Chemistry·Toshio MuraseMinoru Okubo
May 3, 2011·Clinica Chimica Acta; International Journal of Clinical Chemistry·Katsuyuki NakajimaAkira Tanaka
Oct 16, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·J S CohnJ Davignon
Mar 2, 2018·Current Opinion in Endocrinology, Diabetes, and Obesity·Katsuyuki Nakajima, Akira Tanaka
Apr 7, 1999·Current Opinion in Cardiology·L J SemanE J Schaefer
Aug 12, 2008·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Genovefa D KolovouDennis V Cokkinos
Jan 13, 2005·Journal of Atherosclerosis and Thrombosis·Akira Tanaka
Nov 5, 2008·Journal of Atherosclerosis and Thrombosis·Takeyoshi MuranoKohji Shirai
Jan 17, 1995·Annals of the New York Academy of Sciences·A TanakaF Numano
Jul 1, 2018·The Journal of Applied Laboratory Medicine·Yuhko HiraoYasuki Ito
Jan 9, 2018·Clinica Chimica Acta; International Journal of Clinical Chemistry·Katsuyuki Nakajima, Akira Tanaka
May 16, 2000·Clinica Chimica Acta; International Journal of Clinical Chemistry·M OkazakiK Nakajima
Aug 26, 1998·Clinica Chimica Acta; International Journal of Clinical Chemistry·A TanakaF Numano
Nov 26, 2010·Annals of Clinical Biochemistry·Takamitsu NakanoKatsuyuki Nakajima

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.